SMITHKLINE BEECHAM PHARMACEUTICALS (INDIA)
Article Abstract:
The net profit of SmithKline Beecham Pharmaceuticals (India) Ltd (SKBP) increased by 71.7 percent to Rs331.90 million for the year ended December 1997. Is sales increased by 28.5 percent. It has set up two facilities in Bangalore and Mysore. Its formulations include Iodex, Zevit, Zental, Augmentini, Dependal-M, Engerix-B and Fefol-Z. It is likely to record a 25 percent sales growth per annum in the next few years. (rk) ------------------------------------------------------------ Financial Performance of SmithKline Beecham Pharmaceuticals (India) Ltd (Rs in million) ------------------------------------------------------------ Particulars Year ended December 1997 ------------------------------------------------------------ Sales 2,595.00 ------------------------------------------------------------ Gross profit 534.20 ------------------------------------------------------------ Net profit 331.90 ------------------------------------------------------------ Equity 147.00 ------------------------------------------------------------ Earnings per share (Rs) 22.60 ------------------------------------------------------------ Market price of share (Rs) 795.00 ------------------------------------------------------------
Comment:
Registers 71.7% increase in net profit to Rs331.90 mil on sales of Rs2,595 mil for the year ended 12/97
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
LOSING ITS CAHRGE
Article Abstract:
The dry cell battery segment has a market size of about Rs12 billion. The segment is classified into zinc carbon and alkaline batteries. The alkaline battery sales at 17 million units in 1997- 98 formed only one percent of the 1.8 billion units battery market. The alkaline battery market is said to grow at a higher rate due to projected rise in the sale of small devices and other electronic gadgets, which use alkaline batteries. While multinational players like Sony, Ralston Purina and Matsushita are importing and marketing alkaline batteries, Duracell has invested Rs500 million in a plant in Gurgaon to produce 50 million batteries per annum. The BPL group's Rs1.1 billion plant in Karnataka has commenced production of Alkaline batteries. The Indian players manufacturing zinc chloride batteries have upgraded their product range by making longer lasting batteries. In the zinc chloride segment, while Matsushita's Nippo and Novino brands hold 51 percent marketshare, Eveready holds 42 percent and Geep Industries the rest. With the exception of Geep Industries, all the zinc chloride players have launched alkaline batteries. The overall growth rate of the dry cell battery market has dropped to five percent from 20 percent due to the slump in the economy. (tsm)
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic: